🎧 Listen to this interview from #ESMO2025 with Prof. @MRoupret (FR) joining Dr. @BenjaminPradere to discuss the phase III ALBAN trial: Atezolizumab + BCG vs BCG alone in BCG-naïve, high-risk #NMIBC. Learn more 👇 https://t.co/7z58EpqM2x #bladdercancer #oncology

In this exclusive interview from #ESMO2025, Prof. Nicholas James (GB) shares the 📊 final survival analysis from the BladderPath trial - comparing upfront MRI vs TURBT for staging new bladder cancers, with Dr. @BenjaminPradere 🎧Listen here 👇 https://t.co/xClWW8xXX3

📋Recommendations for AE management & procedural best practices for IDRS 🥨🥨🥨 👀OPEN ACCESS, read it: https://t.co/QLzCD0xcZt 👥Collaborative review with 🔝 co-authors: @BenjaminPradere @DrShariat @BerUrologia @spsutkaMD among others!

Humbled to present at this amazing conference organized by @jteoh_hk with @Albert0Briganti @BenjaminPradere @alexandracomte @amassonlecomte @jleow @Cacciamani_MD @DocGauhar Title of talk not chosen by me!

🎯@BenjaminPradere (@UROSUD) sharing insights on “How to Conduct a High-Quality Randomized Trial: A Practical Guide” at the ARISTA Program @CUHKMedicine 🔑Key takeaways: • Design trials with clear, answerable questions • Ensure rigorous methodology and transparency •

🤩Great session in FOCUS Toulouse 🥰More than happy to share stage with @MRoupret @drenriquegrande @OncoBellmunt @BenjaminPradere @Achard_Verane ⚠️I was the only one with the perfect flag socks!

🔥Just in @BJUIjournal! 🥇The first structured training curriculum for RARNU using international expert consensus Link🔗 https://t.co/kPUUkhhxPB @FarshadSheybaee @RKSayyid @Hoomandjaladat

TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4) https://t.co/FQFqfdbyEn The phase 2 SunRISe-4🌄 trial evaluated

🚨Interim results of SR-4 study published in @TheLancetOncol 📉pCR rate 42% 🔗Download it here: https://t.co/vrOk5UdIeF 🤩Glad to co-author this paper with @AndreaNecchi @BerUrologia @tompowles1 @BenjaminPradere among others!

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided

📹 At #UROonco25, Dr. @BenjaminPradere interviewed Dr. @frasor86 about distal ureterectomy for #UTUC. Hear insights on kidney-sparing surgery, high-risk patient selection and key studies. Watch here 👇 https://t.co/IU2zQTzAik

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment @Uroweb @EAU_Uroonco @EAUYAUrology

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol https://t.co/trmFp9Yd0y There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

@Uromigos @UroDocAsh @tompowles1 @UroCancerMD @MarkTysonMD @SBoorjian @AdityaBagrodia @LoebStacy @uretericbud @angiesmith_uro Trying to keep up with the @Uromigos on this whirlwind tour through the rapidly evolving landscape of therapies in NMIBC. @UroDocAsh @siadaneshmand @PGrivasMDPhD @LauraBukavinaMD @AndreaNecchi @MattGalsky @BenjaminPradere @IBCG_BladderCA @MarkTysonMD @MaxKates @UroCancerMD

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday >

Great pleasure during #AUA25 to discuss with @JoshMeeks and @UroDocAsh the futur of BCG naive field The tremendous @IBCG_BladderCA plenary session was fantastic, really enjoyed our debate leaded by @LAUrology_NL https://t.co/VBpIdSlcUi

The International Bladder Cancer Group (IBCG) is pleased to announce the #IBCG2025 Travel Award, designed to support outstanding fellows and early-career academic faculty who are committed to advancing the field of bladder cancer. For more information and to apply:

🤩Happy to be included in the @Uroweb email with our Podcast speaking about the most recent news at @AmerUrological 🙌🏼Thanks to my friend @BenjaminPradere for the nice conversations! 👂You can listen to it here: https://t.co/XKbdUyS1r7

Great meeting in Naples! @EAU_YAUrotheli present! Thanks to the organisers @PandolfoSD @danieleamparore @Ric_Campi @Uroweb